{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T07:38:42Z","timestamp":1780817922941,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["No 777500"],"award-info":[{"award-number":["No 777500"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Few new drugs have been developed for chronic pain. Drug development is challenged by uncertainty about whether the drug engages the human target sufficiently to have a meaningful pharmacodynamic effect. IMI2-PainCare-BioPain-RCT1 is one of four similarly designed studies that aim to link different functional biomarkers of drug effects on the nociceptive system that could serve to accelerate the future development of analgesics. This study focusses on biomarkers derived from nerve excitability testing (NET) using threshold tracking of the peripheral nervous system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a multisite single-dose, subject and assessor-blind, randomized, placebo-controlled, 4-period, 4-way crossover, pharmacodynamic (PD), and pharmacokinetic (PK) study in healthy subjects. Biomarkers derived from NET of large sensory and motor fibers and small sensory fibers using perception threshold tracking will be obtained before and three times after administration of three medications known to act on the nociceptive system (lacosamide, pregabalin, tapentadol) and placebo, given as a single oral dose with at least 1\u2009week apart. Motor and sensory NET will be assessed on the right wrist in a non-sensitized normal condition while perception threshold tracking will be performed bilaterally on both non-sensitized and sensitized forearm skin. Cutaneous high-frequency electrical stimulation is used to induce hyperalgesia. Blood samples will be taken for pharmacokinetic purposes and pain ratings as well as predictive psychological traits will be collected. A sequentially rejective multiple testing approach will be used with overall alpha error of the primary analysis split across the two primary outcomes: strength-duration time constant (SDTC; a measure of passive membrane properties and nodal persistent Na<jats:sup>+<\/jats:sup> conductance) of large sensory fibers and SDTC of large motor fibers comparing lacosamide and placebo. The key secondary endpoint is the SDTC measured in small sensory fibers. Remaining treatment arm effects on key NET outcomes and PK modelling are other prespecified secondary or exploratory analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Measurements of NET using threshold tracking protocols are sensitive to membrane potential at the site of stimulation. Sets of useful indices of axonal excitability collectively may provide insights into the mechanisms responsible for membrane polarization, ion channel function, and activity of ionic pumps during the process of impulse conduction. IMI2-PainCare-BioPain-RCT1 hypothesizes that NET can serve as biomarkers of target engagement of analgesic drugs in this compartment of the nociceptive system for future Phase 1 clinical trials. Phase 2 and 3 clinical trials could also benefit from these tools for patient stratification.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This trial was registered 25\/06\/2019 in EudraCT (2019-000942-36).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06087-1","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T15:04:44Z","timestamp":1645283084000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET)"],"prefix":"10.1186","volume":"23","author":[{"given":"Zahra","family":"Nochi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Pia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Bloms-Funke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmgard","family":"Boesl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Caspani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya C.","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Genser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Kostenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Mouraux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Pelz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Pogatzki-Zahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Schnetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Schubart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Stouffs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Tracey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1aki F.","family":"Troconiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Truini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Van Niel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Miguel","family":"Vela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vollert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishvarani","family":"Wanigasekera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Wittayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Tankisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5541-0240","authenticated-orcid":false,"given":"Nanna B.","family":"Finnerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith G.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf-Detlef","family":"Treede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,19]]},"reference":[{"issue":"4","key":"6087_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/j.pain.0000000000000454","volume":"157","author":"ASC Rice","year":"2016","unstructured":"Rice ASC, Smith BH, Blyth FM. Pain and the global burden of disease. Pain. 2016;157(4):791\u20136. https:\/\/doi.org\/10.1097\/j.pain.0000000000000454.","journal-title":"Pain."},{"issue":"1","key":"6087_CR2","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s13063-021-05272-y","volume":"22","author":"A Mouraux","year":"2021","unstructured":"Mouraux A, Bloms-Funke P, Boesl I, Caspani O, Chapman SC, Di Stefano G, et al. IMI2-PainCare-BioPain-RCT3: a randomized double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by electroencephalography (EEG). Trials. 2021;22(1):404. https:\/\/doi.org\/10.1186\/s13063-021-05272-y.","journal-title":"Trials."},{"key":"6087_CR3","doi-asserted-by":"publisher","unstructured":"Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human peripheral nerve, Muscle Nerve. 1998;21(2):137\u201358. https:\/\/doi.org\/10.1002\/(sici)1097-4598(199802)21:2<137::aid-mus1>3.0.co;2-c.","DOI":"10.1002\/(sici)1097-4598(199802)21:2<137::aid-mus1>3.0.co;2-c"},{"issue":"Pt 12","key":"6087_CR4","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1093\/brain\/123.12.2542","volume":"123","author":"MC Kiernan","year":"2000","unstructured":"Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain. 2000;123(Pt 12):2542\u201351. https:\/\/doi.org\/10.1093\/brain\/123.12.2542.","journal-title":"Brain"},{"issue":"7","key":"6087_CR5","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.clinph.2021.02.397","volume":"132","author":"AG Kristensen","year":"2021","unstructured":"Kristensen AG, Gylfadottir S, Itani M, Kuwabara S, Kr\u00f8ig\u00e5rd T, Khan KS, et al. Sensory and motor axonal excitability testing in early diabetic neuropathy. Clin Neurophysiol. 2021;132(7):1407\u201315. https:\/\/doi.org\/10.1016\/j.clinph.2021.02.397.","journal-title":"Clin Neurophysiol."},{"issue":"5","key":"6087_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/WCO.0b013e3283304c9d","volume":"22","author":"C Krarup","year":"2009","unstructured":"Krarup C, Moldovan M. Nerve conduction and excitability studies in peripheral nerve disorders. Curr Opin Neurol. 2009;22(5):460\u20136. https:\/\/doi.org\/10.1097\/WCO.0b013e3283304c9d.","journal-title":"Curr Opin Neurol."},{"issue":"3","key":"6087_CR7","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1152\/jn.00629.2019","volume":"124","author":"J Tigerholm","year":"2020","unstructured":"Tigerholm J, Hoberg TN, Br\u00f8nnum D, Vittinghus M, Frahm KS, M\u00f8rch CD. Small and large cutaneous fibers display different excitability properties to slowly increasing ramp pulses. J Neurophysiol. 2020;124(3):883\u201394. https:\/\/doi.org\/10.1152\/jn.00629.2019.","journal-title":"J Neurophysiol"},{"issue":"4","key":"6087_CR8","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1523\/JNEUROSCI.1222-03.2004","volume":"24","author":"T Klein","year":"2004","unstructured":"Klein T, Magerl W, Hopf HC, Sandkuhler J, Treede RD. Perceptual correlates of nociceptive long-term potentiation and long-term depression in humans. J Neurosci. 2004;24(4):964\u201371. https:\/\/doi.org\/10.1523\/JNEUROSCI.1222-03.2004.","journal-title":"J Neurosci."},{"issue":"8","key":"6087_CR9","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1152\/jn.00651.2013","volume":"111","author":"EN van den Broeke","year":"2014","unstructured":"van den Broeke EN, Mouraux A. High-frequency electrical stimulation of the human skin induces heterotopical mechanical hyperalgesia, heat hyperalgesia, and enhanced responses to nonnociceptive vibrotactile input. J Neurophysiol. 2014;111(8):1564\u201373. https:\/\/doi.org\/10.1152\/jn.00651.2013.","journal-title":"J Neurophysiol"},{"issue":"9","key":"6087_CR10","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1517\/13543784.2010.511174","volume":"19","author":"G McCleane","year":"2010","unstructured":"McCleane G. Lacosamide for pain. Expert Opinion on Investigational Drugs. 2010;19(9):1129\u201334. https:\/\/doi.org\/10.1517\/13543784.2010.511174.","journal-title":"Expert Opinion on Investigational Drugs."},{"issue":"4","key":"6087_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2337\/dc09-1578","volume":"33","author":"D Ziegler","year":"2010","unstructured":"Ziegler D, Hidvegi T, Gurieva I, Bongardt S, Freynhagen R, Sen D, et al. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care. 2010;33(4):839\u201341. https:\/\/doi.org\/10.2337\/dc09-1578.","journal-title":"Diabetes Care."},{"issue":"8","key":"6087_CR12","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.jpain.2009.01.322","volume":"10","author":"A Shaibani","year":"2009","unstructured":"Shaibani A, Fares S, Selam J-L, Arslanian A, Simpson J, Sen D, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain. 2009;10(8):818\u201328. https:\/\/doi.org\/10.1016\/j.jpain.2009.01.322.","journal-title":"J Pain."},{"issue":"2","key":"6087_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/01.ajp.0000210957.39621.b2","volume":"23","author":"RL Rauck","year":"2007","unstructured":"Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007;23(2):150\u20138. https:\/\/doi.org\/10.1097\/01.ajp.0000210957.39621.b2.","journal-title":"Clin J Pain."},{"issue":"5","key":"6087_CR14","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/AJP.0b013e318196d2b6","volume":"25","author":"JP Wymer","year":"2009","unstructured":"Wymer JP, Simpson J, Sen D, Bongardt S. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. 2009;25(5):376\u201385. https:\/\/doi.org\/10.1097\/AJP.0b013e318196d2b6.","journal-title":"Clin J Pain."},{"issue":"2","key":"6087_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/brain\/awy329","volume":"142","author":"BTA de Greef","year":"2019","unstructured":"de Greef BTA, Hoeijmakers JGJ, Geerts M, Oakes M, Church TJE, Waxman SG, et al. Lacosamide in patients with Nav1.7 mutations-related small fibre neuropathy: a randomized controlled trial. Brain. 2019;142(2):263\u201375. https:\/\/doi.org\/10.1093\/brain\/awy329.","journal-title":"Brain."},{"key":"6087_CR16","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/brain\/awy329","volume":"39","author":"B Namer","year":"2019","unstructured":"Namer B, Schmidt D, Eberhardt E, Maroni M, Dorfmeister E, Kleggetveit IP, et al. Pain relief in a neuropathy patient by lacosamide: proof of principle of clinical translation from patient-specific iPS cell-derived nociceptors. EBioMedicine. 2019;39:401\u20138. https:\/\/doi.org\/10.1093\/brain\/awy329.","journal-title":"EBioMedicine."},{"issue":"1","key":"6087_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1528-1167.2012.03725.x","volume":"54","author":"W Cawello","year":"2013","unstructured":"Cawello W, B\u00f6kens H, Nickel B, Andreas J-O, Halabi A. Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment: LCM Tablet\/Syrup Bioequiv and Saliva PK. Epilepsia. 2013;54(1):81\u20138. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03725.x.","journal-title":"Epilepsia."},{"issue":"1\u20132","key":"6087_CR18","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000339077","volume":"90","author":"W Cawello","year":"2012","unstructured":"Cawello W, Bonn R, Boekens H. Bioequivalence of intravenous and oral formulations of the antiepileptic drug lacosamide. Pharmacology. 2012;90(1\u20132):40\u20136. https:\/\/doi.org\/10.1159\/000339077.","journal-title":"Pharmacology."},{"issue":"8","key":"6087_CR19","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1177\/0091270009352087","volume":"50","author":"HN Bockbrader","year":"2010","unstructured":"Bockbrader HN, Radulovic LL, Posvar EL, Strand JC, Alvey CW, Busch JA, et al. Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol. 2010;50(8):941\u201350. https:\/\/doi.org\/10.1177\/0091270009352087.","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"6087_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40261-014-0211-4","volume":"34","author":"ML Chew","year":"2014","unstructured":"Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, et al. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. Clin Drug Investig. 2014;34(9):617\u201326. https:\/\/doi.org\/10.1007\/s40261-014-0211-4.","journal-title":"Clin Drug Investig."},{"issue":"2","key":"6087_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40268-015-0094-8","volume":"15","author":"A Filipe","year":"2015","unstructured":"Filipe A, Almeida S, Pedroso PF, Neves R, Marques S, Sicard E, et al. Single-dose, randomized, open-label, two-way, crossover bioequivalence study of two formulations of pregabalin 300\u2009mg hard capsules in healthy volunteers under fasting conditions. Drugs R D. 2015;15(2):195\u2013201. https:\/\/doi.org\/10.1007\/s40268-015-0094-8.","journal-title":"Drugs R D."},{"issue":"6","key":"6087_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/AAP.0b013e3181fa6b7a","volume":"35","author":"A Buvanendran","year":"2010","unstructured":"Buvanendran A, Kroin JS, Kari M, Tuman KJ. Can a single dose of 300\u2009mg of pregabalin reach acute antihyperalgesic levels in the central nervous system?: Regional Anesthesia and. Pain Med. 2010;35(6):535\u20138. https:\/\/doi.org\/10.1097\/AAP.0b013e3181fa6b7a.","journal-title":"Pain Med"},{"issue":"1","key":"6087_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1185\/03007995.2010.537589","volume":"27","author":"S Schwartz","year":"2011","unstructured":"Schwartz S, Etropolski M, Shapiro DY, Okamoto A, Lange R, Haeussler J, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151\u201362. https:\/\/doi.org\/10.1185\/03007995.2010.537589.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"6087_CR24","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.2337\/dc13-2291","volume":"37","author":"AI Vinik","year":"2014","unstructured":"Vinik AI, Shapiro DY, Rauschkolb C, Lange B, Karcher K, Pennett D, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37(8):2302\u20139. https:\/\/doi.org\/10.2337\/dc13-2291.","journal-title":"Diabetes Care."},{"issue":"7","key":"6087_CR25","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.pain.2011.02.037","volume":"152","author":"DB Pfau","year":"2011","unstructured":"Pfau DB, Klein T, Putzer D, Pogatzki-Zahn EM, Treede RD, Magerl W. Analysis of hyperalgesia time courses in humans after painful electrical high-frequency stimulation identifies a possible transition from early to late LTP-like pain plasticity. Pain. 2011;152(7):1532\u20139. https:\/\/doi.org\/10.1016\/j.pain.2011.02.037.","journal-title":"Pain."},{"issue":"6","key":"6087_CR26","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/cpt.1096","volume":"104","author":"MO Kovalchuk","year":"2018","unstructured":"Kovalchuk MO, Heuberger JAAC, Sleutjes BTHM, Ziagkos D, van den Berg LH, Ferguson TA, et al. Acute effects of riluzole and retigabine on axonal excitability in patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled, crossover trial. Clin Pharmacol Ther. 2018;104(6):1136\u201345. https:\/\/doi.org\/10.1002\/cpt.1096.","journal-title":"Clin Pharmacol Ther."},{"issue":"5","key":"6087_CR27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.clinph.2009.12.034","volume":"121","author":"S Isose","year":"2010","unstructured":"Isose S, Misawa S, Sakurai K, Kanai K, Shibuya K, Sekiguchi Y, et al. Mexiletine suppresses nodal persistent sodium currents in sensory axons of patients with neuropathic pain. Clin Neurophysiol. 2010;121(5):719\u201324. https:\/\/doi.org\/10.1016\/j.clinph.2009.12.034.","journal-title":"Clin Neurophysiol"},{"issue":"6","key":"6087_CR28","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/sim.4780100611","volume":"10","author":"S Senn","year":"1991","unstructured":"Senn S. A random effects model for ordinal responses from a crossover trial. Stat Med. 1993:12(22):214751. Comment on Ezzet F, Whitehead J. Stat Med. 1991;10(6):906\u20137. https:\/\/doi.org\/10.1002\/sim.4780100611.","journal-title":"Stat Med."},{"key":"6087_CR29","first-page":"35","volume-title":"Measures in health psychology: a user\u2019s portfolio causal and control beliefs","author":"R Schwarzer","year":"1995","unstructured":"Schwarzer R, Jerusalem M. Generalized self-efficacy scale. In: Weinman J, Wright S, Johnston M, editors. Measures in health psychology: a user\u2019s portfolio causal and control beliefs. Windsor, UK: NFER-NELSON; 1995. p. 35\u20137."},{"issue":"4","key":"6087_CR30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1037\/1040-3590.7.4.524","volume":"7","author":"MJL Sullivan","year":"1995","unstructured":"Sullivan MJL, Bishop SR, Pivik J. The Pain Catastrophizing Scale: development and validation. Psychol Assess. 1995;7(4):9\u2013532. https:\/\/doi.org\/10.1037\/1040-3590.7.4.524.","journal-title":"Psychol Assess"},{"issue":"1","key":"6087_CR31","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pain.2009.06.020","volume":"146","author":"R Ruscheweyh","year":"2009","unstructured":"Ruscheweyh R, Marziniak M, Stumpenhorst F, Reinholz J, Knecht S. Pain sensitivity can be assessed by self-rating: development and validation of the Pain Sensitivity Questionnaire. Pain. 2009;146(1):65\u201374. https:\/\/doi.org\/10.1016\/j.pain.2009.06.020.","journal-title":"Pain"},{"key":"6087_CR32","unstructured":"Spielberger CD, Gorsuch RL, Lushene RL, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press."},{"issue":"4","key":"6087_CR33","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/sim.3495","volume":"28","author":"F Bretz","year":"2009","unstructured":"Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective multiple test procedures. Statist Med. 2009;28(4):586\u2013604. https:\/\/doi.org\/10.1002\/sim.3495.","journal-title":"Statist Med."},{"issue":"8476","key":"6087_CR34","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"327","author":"J Martin Bland","year":"1986","unstructured":"Martin Bland J. Altman DouglasG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;327(8476):307\u201310. https:\/\/doi.org\/10.1016\/S0140-6736(86)90837-8.","journal-title":"Lancet."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06087-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06087-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06087-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T15:11:40Z","timestamp":1645283500000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06087-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,19]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6087"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06087-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,19]]},"assertion":[{"value":"8 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the IEC of the following sites: Aarhus University (Denmark) (Central Denmark Region Committees on Health Research Ethics, no. 1-10-72-133-19), the Comit\u00e9 d'Ethique hospitalo-facultaire of the Cliniques universitaires Saint-Luc (Belgium), the Ethik-Kommission II der Universit\u00e4t Heidelberg (Germany), and the Comitato Etico Sapienza Universita di Roma (Italy).Written informed consent to participate will be provided by each participant before the start of study assessments or the intervention. These may be requested by contacting sponsor.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"OC, FF, CL, AVK, AM, ZN, HP, ASc, ASt, ES, HT, BG, and VW declare they have no conflict of interest. PBF and JVN were employees of Gr\u00fcnenthal when they contributed to the study protocol, and PBF also reports consultancy fees from ConsulTech. IB is an employee of Gr\u00fcnenthal. NBF reports personal fees from Almirall, NeuroPN, Novartis Pharma, and Vertex and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics, outside the submitted work. SCC is an employee and shareholder of Eli Lilly and Company. KGP is an employee of Eli Lilly and Company. KS is an employee of ConsulTech. TL is an employee of Teva Pharmaceuticals. JVN was an employee of Gr\u00fcnenthal when he contributed to the protocol and reports personal fees from Medwis-extern GmbH & Co.KG, outside the submitted work. AT reports personal fees from Angelini, Almirall, Grunenthal, and Eliem Therapeutics, outside the submitted work. IFT has received personal fees from Gr\u00fcnenthal, outside the submitted work. IT reports personal fees from royalties on books, personal fees from advisory board for Amgen Neuroscience, personal fees from Consultant to Cannbiorex Life 180, personal fees from honoraria for education talks for Gr\u00fcnenthal, outside the submitted work. JV has received personal fees from Vertex Pharmaceuticals and Embody Orthopaedic, outside the submitted work. JMV is an employee of Welab Barcelona. KV reports personal fees from Bayer Healthcare, Gr\u00fcnenthal, Eli Lilly and Company, and AbbVie, outside the submitted work. RDT reports personal fees from Bayer, Gr\u00fcnenthal, GSK, and Sanofi outside the submitted work. In addition, he has a patent DE 103 31 250.1-35 with royalties paid to MRC Systems. MRC Systems (BP and MG) develop, produce, and market products in the field of QST. MW reports personal fees from Novartis, Alnylam, Amicus, Biogen, Bristol-Myers-Squibb, Pfizer, Bial, and other from Boehringer-Ingelheim Foundation, outside the submitted work. EPZ reports fees from Mundipharma, Novartis, and Gr\u00fcnenthal, outside the submitted work. All authors are partners of the IMI2-PainCare consortium ().","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"163"}}